Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand

Cencora (COR) posted fiscal Q4 2026 adjusted EPS of $4.66, topping estimates by 2.2%, as revenue climbed 5.5% to $88.35B.

The beat came from three named drivers: specialty pharmaceutical volumes, GLP-1 drug demand, and the OneOncology acquisition. Together they pushed both the top line and margins higher, according to the report.

Forward guidance matters more for positioning. Management guided fiscal 2027 EPS to $19.40-$19.75, which implies 8-10% growth. Cencora also raised its quarterly dividend by 10%, a direct return-of-capital signal alongside the earnings beat.

Cencora also announced a specialty-focused organizational restructure. Interpretation: the reorganization aligns the company's structure with the same specialty business that powered this quarter's results, suggesting management plans to double down on that segment rather than treat it as a one-quarter tailwind. That reading is analytical, not a company statement.

The EPS beat is modest at 2.2%, so the stock's reaction will likely hinge on whether traders view the $19.40-$19.75 range as conservative or fully priced. The 8-10% growth guide combined with the 10% dividend hike gives both growth and income buyers a reason to engage.